Page 1 | Search Results | Blood | American Society of Hematology

1-9 of 9

Sort by

Sort Order Select

Journal Articles

Long Term Significance of Response in Multiple Myeloma After Stem Cell Transplantation.

Joaquin Martínez-López, Joan Blade, M. Carmen Gomez del Castillo, Maria Victoria Mateos, Adrian Alegre, MD, José Garcia-Laraña, Anna Sureda, Javier de la Rubia, Eulogio Conde, MD, Rafael Martínez, Felipe de Arriba, Jose Luis Gomez Zamudio, Juan Besalduch, Rafael Cabrera, M. Cruz Biguria, Jose Maria Moraleda, J.F San Miguel, Juan José Lahuerta, MD, PhD

Blood (2009) 114 (22): 1811.

https://doi.org/10.1182/blood.V114.22.1811.1811

Published: 2009

Journal Articles

A Prospective, Multicenter, Randomized, Trial of Bortezomib/Melphalan/Prednisone (VMP) Versus Bortezomib/Thalidomide/Prednisone (VTP) as Induction Therapy Followed by Maintenance Treatment with Bortezomib/Thalidomide (VT) Versus Bortezomib/Prednisone (VP) in Elderly Untreated Patients with Multiple Myeloma Older Than 65 Years.

Blood (2009) 114 (22): 3.

https://doi.org/10.1182/blood.V114.22.3.3

Published: 2009

Journal Articles

A Phase I/II, National, Multicenter, Open Label Study of Bortezomib (Velcade) and Fludarabine, Cytarabine and Idarubicin (Flag-Ida) (V-Flag-Ida) in Pts with Relapsed and/or Refractory Acute Myeloblastic Leukemia (AML).

Maria-Victoria Mateos, Rafael Martínez, Salut Brunet, Maria-Belén Vidriales, Albert Oriol, MD, Juan José Lahuerta, MD, PhD, Mari Luz Amigo, Jordi Esteve, Javier de la Rubia, Luis Palomera, Javier Bueno, Jesus F San Miguel

Blood (2009) 114 (22): 4140.

https://doi.org/10.1182/blood.V114.22.4140.4140

Published: 2009

Journal Articles

Impact of FISH and Cytogenetics On Overall and Event Free Survival in Myeloma: An IMWG Analysis of 9,897 Patients.

Blood (2009) 114 (22): 743.

https://doi.org/10.1182/blood.V114.22.743.743

Published: 2009

Journal Articles

Multicenter, Randomized, Open-Label, Phase III Trial of Lenalidomide-Dexamethasone (Len/dex) Vs Therapeutic Abstention in Smoldering Multiple Myeloma at High Risk of Progression to Symptomatic MM: Results of the First Interim Analysis.

Blood (2009) 114 (22): 614.

https://doi.org/10.1182/blood.V114.22.614.614

Published: 2009

Journal Articles

Natural History of Multiple Myeloma Relapsing After Therapy with IMiDs and Bortezomib: A Multicenter International Myeloma Working Group Study.

Blood (2009) 114 (22): 2878.

https://doi.org/10.1182/blood.V114.22.2878.2878

Published: 2009

Journal Articles

Final Results of a Phase II Trial with Plitidepsin (Aplidin) Alone and in Combination with Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma

Maria-Victoria Mateos, Mª Teresa Cibeira, Paul Richardson, Joan Blade, Felipe Prosper, MD, Albert Oriol, Javier de la Rubia, MD, Adrian Alegre, MD, Juan José Lahuerta, MD, PhD, Ramón García-Sanz, MD, PhD, Constantine S. Mitsiades, MD, PhD, Jose Espinoza, MD, Kenneth C. Anderson, J.F. San Miguel

Blood (2008) 112 (11): 3700.

https://doi.org/10.1182/blood.V112.11.3700.3700

Published: 2008

Journal Articles

VAMP/ThaCyDex: Velcade® (Bortezomib), Adriamycin, Melphalan and Prednisone Alternating with Thalidomide, Cyclophosphamide and Dexametasone as a Salvage Regimen in Relapsed Multiple Myeloma Patients

Enrique Colado, MD, Maria-Victoria Mateos, MD, PhD, Maria-Jose Moreno, MD, Felipe de Arriba, MD, Javier de la Rubia, MD, Juan José Lahuerta, MD, PhD, Pastora Iniesta, MD, Maria Cruz Viguria, MD, Ana Pilar Gonzalez, MD, Ramón García-Sanz, MD, PhD, Juan Olazabal, MD, Jesús F San Miguel

Blood (2008) 112 (11): 3694.

https://doi.org/10.1182/blood.V112.11.3694.3694

Published: 2008

Journal Articles

Anti-Thymocyte Globulin Induces Higher Response Rates and Less Graft-Versus-Host Disease in Multiple Myeloma Patients Undergoing Allogeneic Stem Cell Transplantation.

Francis Ayuk, MD, José A. Perez-Simon, MD, Avichai Shimoni, MD, Anna Sureda, MD, Tatjana Zabelina, MD, Rainer Schwerdtfeger, MD, Rodrigo Martino, MD, Herbert G. Sayer, MD, Adrián Alegre, MD, Juan-José Lahuerta, MD, Djordje Atanackovic, MD, Christine Wolschke, MD, Arnon Nagler, MD, Axel R. Zander, MD, Jesús San Miguel, MD, Nicolaus Kroeger, MD

Blood (2007) 110 (11): 2980.

https://doi.org/10.1182/blood.V110.11.2980.2980

Published: 2007

NARROW

Long Term Significance of Response in Multiple Myeloma After Stem Cell Transplantation.

A Phase I/II, National, Multicenter, Open Label Study of Bortezomib (Velcade) and Fludarabine, Cytarabine and Idarubicin (Flag-Ida) (V-Flag-Ida) in Pts with Relapsed and/or Refractory Acute Myeloblastic Leukemia (AML).

Impact of FISH and Cytogenetics On Overall and Event Free Survival in Myeloma: An IMWG Analysis of 9,897 Patients.

Multicenter, Randomized, Open-Label, Phase III Trial of Lenalidomide-Dexamethasone (Len/dex) Vs Therapeutic Abstention in Smoldering Multiple Myeloma at High Risk of Progression to Symptomatic MM: Results of the First Interim Analysis.

Natural History of Multiple Myeloma Relapsing After Therapy with IMiDs and Bortezomib: A Multicenter International Myeloma Working Group Study.

Final Results of a Phase II Trial with Plitidepsin (Aplidin) Alone and in Combination with Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma

VAMP/ThaCyDex: Velcade® (Bortezomib), Adriamycin, Melphalan and Prednisone Alternating with Thalidomide, Cyclophosphamide and Dexametasone as a Salvage Regimen in Relapsed Multiple Myeloma Patients

Anti-Thymocyte Globulin Induces Higher Response Rates and Less Graft-Versus-Host Disease in Multiple Myeloma Patients Undergoing Allogeneic Stem Cell Transplantation.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only